Skip to main content
Erschienen in: Applied Health Economics and Health Policy 2-3/2008

01.07.2008 | Original Research Article

The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care

verfasst von: Dr Edward M. Gardner, Moises E. Maravi, Cornelis Rietmeijer, Arthur J. Davidson, William J. Burman

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 2-3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

The association between antiretroviral adherence, healthcare utilization and medical costs has not been well studied.

Objective

To examine the relationship of adherence to antiretroviral medications to healthcare utilization and healthcare costs.

Methods

A retrospective cohort study was conducted using data from 325 previously antiretroviral medication-naive HIV-infected individuals initiating first antiretroviral therapy from 1997 through 2003. The setting was an inner-city safety net hospital and HIV clinic in the US. Adherence was assessed using pharmacy refill data. The average wholesale price was used for prescription costs. Healthcare utilization data and medical costs were obtained from the hospital billing database, and differences according to quartile of adherence were compared using analysis of variance (ANOVA). Multivariate logistic regression was used to assess predictors of higher annual medical costs. Sensitivity analyses were used to examine alternative anti-retroviral pricing schemes. The perspective was that of the healthcare provider, and costs were in year 2005 values.

Results

In 325 patients followed for a mean (± SD) 3.2 (1.9) years, better adherence was associated with lower healthcare utilization but higher total medical costs. Annual non-antiretroviral medical costs were $US7612 in the highest adherence quartile versus $US10 190 in the lowest adherence quartile. However, antiretroviral costs were significantly higher in the highest adherence quartile ($US17 513 vs $US8690), and therefore the total annual medical costs were also significantly higher in the highest versus lowest adherence quartile ($US25 125 vs $US18 880). In multivariate analysis, for every 10% increase in adherence, the odds of having annual medical costs in the highest versus lowest quartile increased by 87% (odds ratio 1.87; 95% CI 1.45, 2.40). In sensitivity analyses, very low antiretroviral prices (as seen in resource-limited settings) inverted this relationship — excellent adherence was cost saving.

Conclusion

Better adherence to antiretroviral medication was associated with decreased healthcare utilization and associated costs; however, because of the high cost of antiretroviral therapy, total medical costs were increased. Combination antiretroviral therapy is known to be cost effective; lower anti-retroviral costs may make it cost saving as well.
Literatur
1.
Zurück zum Zitat Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001 Mar 15; 344(11): 817–23PubMedCrossRef Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001 Mar 15; 344(11): 817–23PubMedCrossRef
2.
Zurück zum Zitat Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active anti-retroviral therapy. Antivir Ther 2002 Dec; 7(4): 257–66PubMed Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active anti-retroviral therapy. Antivir Ther 2002 Dec; 7(4): 257–66PubMed
3.
Zurück zum Zitat Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006 Apr 1; 42(7): 1003–10PubMedCrossRef Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006 Apr 1; 42(7): 1003–10PubMedCrossRef
4.
Zurück zum Zitat Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006 Nov; 44(11): 990–7PubMedCrossRef Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006 Nov; 44(11): 990–7PubMedCrossRef
5.
Zurück zum Zitat Rietmeijer CA, Davidson AJ, Foster CT, et al. Cost of care for patients with human immunodeficiency virus infection: patterns of utilization and charges in a public health care system. Arch Intern Med 1993 Jan 25; 153(2): 219–25PubMedCrossRef Rietmeijer CA, Davidson AJ, Foster CT, et al. Cost of care for patients with human immunodeficiency virus infection: patterns of utilization and charges in a public health care system. Arch Intern Med 1993 Jan 25; 153(2): 219–25PubMedCrossRef
6.
Zurück zum Zitat Keiser P, Nassar N, Kvanli MB, et al. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001 May 1; 27(1): 14–9PubMed Keiser P, Nassar N, Kvanli MB, et al. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001 May 1; 27(1): 14–9PubMed
7.
Zurück zum Zitat Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 Mar 26; 338(13): 853–60PubMedCrossRef Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 Mar 26; 338(13): 853–60PubMedCrossRef
8.
Zurück zum Zitat Tramarin A, Campostrini S, Postma MJ, et al. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics 2004; 22(1): 43–53PubMedCrossRef Tramarin A, Campostrini S, Postma MJ, et al. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics 2004; 22(1): 43–53PubMedCrossRef
9.
Zurück zum Zitat Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc 2006; 4: 20PubMedCrossRef Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc 2006; 4: 20PubMedCrossRef
10.
Zurück zum Zitat Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001 Mar 15; 344(11): 824–31PubMedCrossRef Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001 Mar 15; 344(11): 824–31PubMedCrossRef
11.
Zurück zum Zitat Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001 Jan; 2(1): 52–8PubMedCrossRef Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001 Jan; 2(1): 52–8PubMedCrossRef
12.
Zurück zum Zitat Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS 1999 Jun 18; 13(9): 1115–22PubMedCrossRef Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS 1999 Jun 18; 13(9): 1115–22PubMedCrossRef
13.
Zurück zum Zitat Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Medicine 2006 Jan; 3(1): e4PubMedCrossRef Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Medicine 2006 Jan; 3(1): e4PubMedCrossRef
14.
Zurück zum Zitat Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001 Jun 15; 15(9): 1181–3PubMedCrossRef Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001 Jun 15; 15(9): 1181–3PubMedCrossRef
15.
Zurück zum Zitat Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002 May 3; 16(7): 1051–8PubMedCrossRef Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002 May 3; 16(7): 1051–8PubMedCrossRef
16.
Zurück zum Zitat Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000 Jul 4; 133(1): 21–30PubMed Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000 Jul 4; 133(1): 21–30PubMed
17.
Zurück zum Zitat Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med 2003 Jan 21; 138(2): 143–9PubMed Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med 2003 Jan 21; 138(2): 143–9PubMed
18.
Zurück zum Zitat Gardner EM, Burman WJ, Maravi ME, et al. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005 Nov 1; 40(3): 294–300PubMedCrossRef Gardner EM, Burman WJ, Maravi ME, et al. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005 Nov 1; 40(3): 294–300PubMedCrossRef
19.
Zurück zum Zitat Gardner EM, Burman WJ, Maravi ME, et al. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDs 2006 Sep; 20(9): 628–36PubMedCrossRef Gardner EM, Burman WJ, Maravi ME, et al. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDs 2006 Sep; 20(9): 628–36PubMedCrossRef
20.
Zurück zum Zitat Wood E, Hogg RS, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival response to modern anti-retroviral therapy? AIDS 2003 Mar 28; 17(5): 711–20PubMedCrossRef Wood E, Hogg RS, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival response to modern anti-retroviral therapy? AIDS 2003 Mar 28; 17(5): 711–20PubMedCrossRef
21.
Zurück zum Zitat Red book: pharmacy’s fundamental reference. Montvale (NJ): Thomson Healthcare, Inc., 2005 Red book: pharmacy’s fundamental reference. Montvale (NJ): Thomson Healthcare, Inc., 2005
22.
Zurück zum Zitat Industry data. Producer price index - PPI. Washington, DC: US Department of Labor, Bureau of Labor Statistics [online]. Available from URL: http://www.bls.gov/data/ [Accessed 2007 May 11] Industry data. Producer price index - PPI. Washington, DC: US Department of Labor, Bureau of Labor Statistics [online]. Available from URL: http://​www.​bls.​gov/​data/​ [Accessed 2007 May 11]
23.
Zurück zum Zitat Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007 May; 4(2): 65–72PubMedCrossRef Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007 May; 4(2): 65–72PubMedCrossRef
24.
Zurück zum Zitat Duncan DB. Multiple range and multiple F tests. Biometrics 1955; 11: 1–42CrossRef Duncan DB. Multiple range and multiple F tests. Biometrics 1955; 11: 1–42CrossRef
25.
Zurück zum Zitat Gencarelli DM. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? NHPF Issue Brief 2002 Jun 7; (775): 1–19 Gencarelli DM. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? NHPF Issue Brief 2002 Jun 7; (775): 1–19
26.
Zurück zum Zitat Public Health Services Act, 42 United States Code, Section 256b. Limitation on prices of drugs purchased by covered entities. Public Health Services Act, 42 United States Code, Section 256b. Limitation on prices of drugs purchased by covered entities.
27.
Zurück zum Zitat Steinbrook R. Thailand and the compulsory licensing of efavirenz. N Engl J Med 2007 Feb 8; 356(6): 544–6PubMedCrossRef Steinbrook R. Thailand and the compulsory licensing of efavirenz. N Engl J Med 2007 Feb 8; 356(6): 544–6PubMedCrossRef
28.
Zurück zum Zitat Acurcio Fde A, Puig-Junoy J, Bonolo Pde F, et al. Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil [in Spanish]. Rev Esp Salud Publica 2006 Jan-Feb; 80(1): 41–54PubMedCrossRef Acurcio Fde A, Puig-Junoy J, Bonolo Pde F, et al. Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil [in Spanish]. Rev Esp Salud Publica 2006 Jan-Feb; 80(1): 41–54PubMedCrossRef
29.
Zurück zum Zitat Purdum AG, Johnson KA, Globe DR. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care 2004 Aug; 16(6): 767–80PubMedCrossRef Purdum AG, Johnson KA, Globe DR. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care 2004 Aug; 16(6): 767–80PubMedCrossRef
30.
Zurück zum Zitat Nachega J, Hislop M, Omer S, et al. Effect of adherence to NNRTI-based ART on health care costs in a private sector HIV/AIDS management program in southern Africa. [abstract no. 548]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA) Nachega J, Hislop M, Omer S, et al. Effect of adherence to NNRTI-based ART on health care costs in a private sector HIV/AIDS management program in southern Africa. [abstract no. 548]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)
31.
Zurück zum Zitat White TJ, Vanderplas A, Chang E, et al. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manage Health Outcomes 2004; 12(3): 181–8CrossRef White TJ, Vanderplas A, Chang E, et al. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manage Health Outcomes 2004; 12(3): 181–8CrossRef
32.
Zurück zum Zitat Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006 Apr; 44(4): 300–3PubMedCrossRef Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006 Apr; 44(4): 300–3PubMedCrossRef
33.
Zurück zum Zitat White TJ, Vanderplas A, Ory C, et al. Economic impact of patient adherence with antidepressant therapy within a managed care organization. Dis Manage Health Outcomes 2003; 11(12): 817–22CrossRef White TJ, Vanderplas A, Ory C, et al. Economic impact of patient adherence with antidepressant therapy within a managed care organization. Dis Manage Health Outcomes 2003; 11(12): 817–22CrossRef
34.
Zurück zum Zitat Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003 Nov 18; 139(10): 810–6PubMed Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003 Nov 18; 139(10): 810–6PubMed
35.
Zurück zum Zitat Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005 Jan; 17(1): 10–22PubMedCrossRef Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005 Jan; 17(1): 10–22PubMedCrossRef
36.
Zurück zum Zitat Kumarasamy N. Generic antiretroviral drugs: will they be the answer to HIV in the developing world? Lancet 2004 Jul 3–9; 364(9428): 3–4PubMedCrossRef Kumarasamy N. Generic antiretroviral drugs: will they be the answer to HIV in the developing world? Lancet 2004 Jul 3–9; 364(9428): 3–4PubMedCrossRef
37.
Zurück zum Zitat Kumarasamy N, Vallabhaneni S, Flanigan TP, et al. Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS 2005 Mar 24; 19(6): 625–7PubMedCrossRef Kumarasamy N, Vallabhaneni S, Flanigan TP, et al. Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS 2005 Mar 24; 19(6): 625–7PubMedCrossRef
38.
Zurück zum Zitat Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004 Jul 3–9; 364(9428): 29–34PubMedCrossRef Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004 Jul 3–9; 364(9428): 29–34PubMedCrossRef
39.
Zurück zum Zitat Sansom SL, Anthony MN, Garland WH, et al. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization. AIDS Patient Care STDs 2008 Feb; 22(2): 131–8PubMedCrossRef Sansom SL, Anthony MN, Garland WH, et al. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization. AIDS Patient Care STDs 2008 Feb; 22(2): 131–8PubMedCrossRef
40.
Zurück zum Zitat Press N, Tyndall MW, Wood E, et al. Virologic and im-munologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002 Dec 15; 31 Suppl. 3: S112–7PubMedCrossRef Press N, Tyndall MW, Wood E, et al. Virologic and im-munologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002 Dec 15; 31 Suppl. 3: S112–7PubMedCrossRef
41.
Zurück zum Zitat Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003 Dec 1; 115(8): 632–41PubMedCrossRef Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003 Dec 1; 115(8): 632–41PubMedCrossRef
Metadaten
Titel
The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care
verfasst von
Dr Edward M. Gardner
Moises E. Maravi
Cornelis Rietmeijer
Arthur J. Davidson
William J. Burman
Publikationsdatum
01.07.2008
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 2-3/2008
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/BF03256129

Weitere Artikel der Ausgabe 2-3/2008

Applied Health Economics and Health Policy 2-3/2008 Zur Ausgabe